MSD accused of breaching UK competition law
admin 24th May 2017 Uncategorised 0The UK’s Competition and Markets Authority (CMA) has provisionally found that a discount scheme operated by MSD for its biologic Remicade may have restricted competition from cheaper biosimilar versions of the drug entering the market.
More: MSD accused of breaching UK competition law
Source: News